Literature DB >> 9358995

An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation.

M M Horowitz1, P A Rowlings.   

Abstract

The International Bone Marrow Transplant Registry (IBMTR) and the Autologous Blood and Marrow Transplant Registry (ABMTR) are international research organizations that collect and analyze data on recipients of allogeneic and autologous hematopoietic stem cell transplants, respectively. Over 300 institutions in 47 countries contribute data to the IBMTR and over 150 institutions in North and South America contribute data to the ABMTR. The IBMTR and ABMTR database have information on more than 65,000 transplant recipients, about 40% of allogeneic transplantations performed since 1964, and about half of all autotransplantations in North and South America since 1989. Current transplant activity, as reported to the IBMTR and ABMTR, is summarized in this article as well as key findings from recent IBMTR and ABMTR studies.

Mesh:

Year:  1997        PMID: 9358995     DOI: 10.1097/00062752-199704060-00006

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  10 in total

Review 1.  Stem cell transplantation for autoimmune diseases.

Authors:  J Moore; P Brooks
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Harvesting blood stem cells from cranial bone at craniotomy--a preliminary study.

Authors:  Tomomi Iwashita; Tsuyoshi Tada; Hua Zhan; Yuichiro Tanaka; Kazuhiro Hongo
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

3.  Late congestive heart failure after hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Liton Francisco; Julia Steinberger; Seira Kurian; F Lennie Wong; Jon Sharp; Richard Sposto; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue.

Authors:  T Tada; T Takizawa; F Nakazato; S Kobayashi; K Koike; M Oguchi; E Ishii; Y Amano
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

5.  Ethnic differences in chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Saro H Armenian; Can-Lan Sun; Jennifer Berano Teh; Mukta Arora; K Scott Baker; Liton Francisco; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

6.  Salvage therapy for relapsed or refractory acute myeloid leukemia.

Authors:  James K Mangan; Selina M Luger
Journal:  Ther Adv Hematol       Date:  2011-04

7.  Successful neoadjuvant synchronous chemo- and radiotherapy for disseminated primary intracranial choriocarcinoma: case report.

Authors:  Teruyoshi Kageji; Shinji Nagahiro; Kazuhito Matsuzaki; Yasuhiko Kanematsu; Minoru Nakatani; Yasuhiko Okamoto; Tsutomu Watanabe
Journal:  J Neurooncol       Date:  2007-01-05       Impact factor: 4.506

8.  Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study.

Authors:  Wei Tang; Xing Fan; Ling Wang; Jiong Hu
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

Review 9.  When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Adam Lamble; Rachel Phelan; Michael Burke
Journal:  J Clin Med       Date:  2017-07-07       Impact factor: 4.241

10.  A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.

Authors:  Ting Yang; Qiaoxian Lin; Jinhua Ren; Ping Chen; Xiaohong Yuan; Xiaofeng Luo; Tingbo Liu; Jing Zheng; Zhihong Zheng; Xiaoyun Zheng; Xinji Chen; Langhui Zhang; Hao Zheng; Zaisheng Chen; Xueling Hua; Shaohua Le; Jian Li; Zhizhe Chen; Jianda Hu
Journal:  Oncotarget       Date:  2016-11-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.